Vivus (VVUS) +6.8% premarket after a study concludes its weight-loss drug Qsymia significantly...
Friday, February 1, 9:02 AM ETVivus (VVUS) +6.8% premarket after a study concludes its weight-loss drug Qsymia significantly improved multiple cardiovascular disease risk factors. The biopharma company says patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles